Context Therapeutics shares surge 10.19% intraday as CTIM-76 receives FDA fast track designation for platinum-resistant ovarian cancer.

Context Therapeutics surged 10.19% intraday, as the company received FDA Fast Track designation for its CLDN6×CD3 bispecific antibody CTIM-76 in the treatment of platinum-resistant ovarian cancer patients who have received all standard therapies. The company is currently conducting a Phase 1 trial of CTIM-76, with interim data expected in June 2026, targeting CLDN6-positive advanced or metastatic ovarian, endometrial, and testicular cancers.